Aluminum Oxide Cassava Dioscorea Villosa Tuber Fra

證據等級: L5

預測適應症: 0 個

Multi-Ingredient Homeopathic Complex: Repurposing Assessment Not Available

One-Sentence Summary

This submission contains a seven-ingredient combination — Aluminum Oxide, Cassava, Dioscorea Villosa Tuber, Frangula Purshiana Bark, Lycopodium Clavatum Spore, Strychnos Nux-Vomica Seed, and Sulfur — whose ingredient profile is consistent with a classical homeopathic preparation. No formal indication, no DrugBank ID, and no TxGNN predictions were returned for this candidate; the pipeline was unable to generate a repurposing signal. Without a structured drug node in the knowledge graph, no evidence-based recommendation can be made at this time.

Quick Overview

Item	Content
Original Indication	Not established
Predicted New Indication	No prediction generated
TxGNN Prediction Score	N/A
Evidence Level	L5 — model prediction only (no predictions returned)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available, and TxGNN returned no predicted indications for this candidate.

The ingredient list closely resembles a classical homeopathic formula. Strychnos Nux-Vomica Seed and Lycopodium Clavatum Spore are among the most commonly used homeopathic constitutional remedies, historically associated with digestive complaints, nausea, and hepatobiliary dysfunction. Frangula Purshiana Bark (cascara) is a known stimulant laxative, and Dioscorea Villosa Tuber has been associated with antispasmodic and hormonal applications in traditional medicine. However, these are folk medicine associations and are not sufficient to anchor a TxGNN knowledge graph node.

Because TxGNN operates on DrugBank-registered single-entity drugs mapped to its knowledge graph, multi-ingredient formulations — especially those without a DrugBank ID — cannot be scored. Until each active ingredient is individually evaluated, or the combination is treated as a named compound with a DrugBank record, no mechanistic repurposing analysis is possible.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

This drug is not marketed and holds no regulatory authorizations.

Safety Considerations

Please refer to the package insert for safety information.

Note on Strychnos Nux-Vomica: At non-homeopathic doses, nux vomica contains strychnine, a potent neurotoxin. If this product is not a homeopathic (ultra-dilute) preparation, a dedicated toxicology review is required before any clinical evaluation proceeds.

Conclusion and Next Steps

Decision: Hold

Rationale: TxGNN returned zero predicted indications because the candidate lacks a DrugBank ID and is not represented as a node in the knowledge graph; without a graph anchor, no repurposing scoring is possible.

To proceed, the following is needed:

Confirm whether this is a homeopathic preparation (ultra-dilute) or a botanical/nutraceutical with measurable active-ingredient concentrations — the two pathways require entirely different evaluation frameworks
Obtain individual DrugBank IDs for each constituent (particularly Dioscorea Villosa, Frangula Purshiana, and Strychnos Nux-Vomica) and run TxGNN on each separately
Retrieve the original product label or prescribing information to establish the intended indication and dosing
If the product is not homeopathic, conduct a strychnine safety assessment given the presence of Nux-Vomica seed
Re-run the Evidence Pack pipeline once a DrugBank-mappable drug node is available
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.